Answers are grounded in this paper and cite their sources.
Cross-sectional study shows 39.2% prevalence of pulmonary hypertension in CKD patients, highlighting associations with disease stage and anemia.
Background: Pulmonary hypertension (PH) is an emerging cardiovascular complication in patients with chronic kidney disease (CKD), especially in advanced stages and end-stage renal disease. It is associated with increased morbidity and mortality[1]. This cross-sectional study assessed the prevalence of PH among non-dialysis and dialysis CKD patients and examined the correlation between PH severity and CKD stage in a tertiary care center. Methods: Atotal of 171 adult CKD patients (Stage III–V) at a tertiary hospital in central India were evaluated. Clinical data, CKD stage (by estimated glomerular filtration rate), and relevant laboratory parameters were recorded. PH was assessed via 2-dimensional echocardiography, defined as pulmonary artery systolic pressure ≥35 mmHg at rest, and categorized as mild, moderate, or severe. Data were analyzed with appropriate statistical tests to identify associations between PH (presence and severity) and CKD stage and other clinical variables. Results: The overall prevalence of PH in the CKD cohort was 39.2% (67 of 171 patients). PH prevalence rose significantly with advancing CKD stage: 14.7% in Stage III, 41.3% in Stage IV, and 47.3% in Stage V (p=0.01)[2][3]. All PH cases were mild-to-moderate; no patient had severe PH. Patients on maintenance hemodialysis had a higher rate of PH than non-dialysis patients (p<0.01). Longer duration of CKD (>5 years) and the presence of an arteriovenous (AV) fistula were associated with higher PH prevalence (p<0.05). There was no significant difference in age or sex distribution between PH and non-PH groups. Among laboratory parameters, only hemoglobin levels were significantly different: PH patients had more severe anemia (mean Hb 7.3±1.2 g/dL) compared to those without PH (9.8±2.1 g/dL, p=0.003)[4][5]. Serum calcium, phosphate, calciumphosphate product, and creatinine did not differ significantly between PH and non-PH groups in this cohort (p>0.3). Conclusions: PH is a common complication in CKD patients, observed in roughly two out of five patients in this study, and its prevalence increases with CKD progression. Advanced CKD (Stage V), coexisting diabetes and hypertension, longer dialysis vintage, and presence of an AV fistula are associated with higher risk of PH. These findings underscore the importance of screening for PH in CKD, particularly in advanced stages, and managing contributory factors like anemia and volume overload to potentially mitigate PH risk.
No takes yet. Share an insight, caveat, or question.
Deepak Assudani (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: